|
During our June 21st session, come learn more about our Two Spirit kin, and their sacred work of continuing to provide Indigenous expansive ways of understanding gender. Two Spirit people have been here for centuries stewarding the well-being of their communities. The Community Collaborative acknowledges our Two Spirit kin and bring them to the fore of our work. |
|
Mayra Colazo, Community Thought Partner
 The Community Collaborative welcomes Mayra Colazo, as our Community Thought Partner co-facilitator for this month. Mayra became a member of the Central Washington Disability Resources team in March 2016 first as an admin and through passion and hard work, she now serves as the Executive Director. Mayra is not only Bilingual (English/Spanish) but champions the leadership of those experiencing disabilities in forming programs, services and policies that are rooted in the leadership of those with lived experiences of disabilities. She provides thought partnership to the Community Collaborative representing Latinx & Disability folks.
|
|
Understanding Long Covid
Long COVID is defined as signs, symptoms, and conditions that continue or develop after initial COVID-19 infection. Dr. Tao Sheng Kwan-Gett will join us to lead a community presentation on Long Covid. Bring all your questions!
Tao Sheng Kwan-Gett, MD, MPH, Chief Science Officer
Dr. Kwan-Gett has long focused on bringing together people, systems, and ideas—building collaborative relationships with state and local public health leaders in rural and urban regions on both sides of the Cascades. Previously he practiced pediatrics at Virginia Mason for over 12 years with an emphasis on behavioral health and did volunteer work with refugee communities globally and locally. As a medical epidemiologist at Public Health Seattle & King County, Tao led a team responsible for communicable disease prevention and control. Tao has also served as a faculty member at the University of Washington School of Public Health.
 2SHB 1745: Improving Diversity in Clinical Trials
Come learn about 2SHB 1745 from Policy Analyst Anna Kelsey with the Executive Office of Policy, Planning & Evaluation. The purpose of 2SHB 1745 is to increase participation and representation of diverse demographic groups in clinical trials of drugs and medical devices. Also learn about DOH's role to produce a legislative report identifying underrepresented demographic groups, barriers to participation, and approaches for improving diversity in clinical trials.
|
|
|
|
